







Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Lu Ping Tan ^{1,2}, Geok Wee Tan ^{1,3}, Vijaya Mohan Sivanesan ¹, Siang Ling Goh⁴, Xun Jin Ng¹, Chun Shen Lim ^{4,5}, Wee Ric Kim¹, Taznim Begam Binti Mohd Mohidin ⁴, Nor Soleha Mohd Dali⁶, Siew Hoon Ong¹, Chun Ying Wong⁷, Halimuddin Sawali⁸, Yoke Yeow Yap^{9,10}, Faridah Hassan¹¹, Kin Choo Pua¹², Cheng Eng Koay^{13,14}, Ching Ching Ng⁴, and Alan Soo-Beng Khoo ¹, the Malaysian Nasopharyngeal Carcinoma Study Group[†]

¹Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

²Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Selangor, Malaysia

³Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁴Faculty of Science, University of Malaya, Institute of Biological Sciences, Kuala Lumpur, Malaysia

⁵Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand

⁶Haematology Unit, Cancer Research Centre, Institute for Medical Research, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

⁷Department of Otorhinolaryngology, Sarawak General Hospital, Ministry of Health Malaysia, Jalan Hospital, Kuching, Sarawak, Malaysia

⁸Department of Otorhinolaryngology, Queen Elizabeth Hospital, Ministry of Health Malaysia, Kota Kinabalu, Sabah, Malaysia

⁹Department of Otorhinolaryngology, Kuala Lumpur Hospital, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

¹⁰Department of Surgery, Clinical Campus Faculty of Medicine and Health Sciences, University Putra Malaysia at Kuala Lumpur Hospital, Ministry of Health Malaysia, Kuala Lumpur, Malaysia

¹¹Department of Otorhinolaryngology, Selayang Hospital, Ministry of Health Malaysia, Batu Caves, Selangor, Malaysia

¹²Department of Otorhinolaryngology, Pulau Pinang Hospital, Ministry of Health Malaysia, Georgetown, Pulau Pinang, Malaysia

¹³Gleneagles Kuala Lumpur Hospital, Kuala Lumpur, Malaysia

¹⁴Sunway Medical Centre, Bandar Sunway, Selangor, Malaysia

Author contributions: L.P.T., G.W.T., S.V.M., S.L.G., C.S.L., T.B.B.M.M., C.C.N. conducted experiments and acquired experimental data. W.R.K., X.J.N., N.S.M.D., C.S.H.O., C.Y.W., C.A.O., Y.Y.Y., F.H., K.C.P., C.E.K. and the M.N.C.S.G. recruited patients, acquired and interpreted clinical data. L.P.T. and G.W.T. analyzed and interpreted data. L.P.T. wrote the manuscript. A.S.B.K. and G.W.T. critically reviewed and improved the manuscript.

Additional Supporting Information may be found in the online version of this article.

Key words: systematic comparison, biomarkers, early detection, prognosis, Epstein–Barr virus, nasopharyngeal carcinoma

Abbreviations: AJCC: American Joint Committee on Cancer; ASR: age standardized rate; AUC: area under curve; EA: early antigen; EBNA-1: EBV nuclear antigen 1; EBV: Epstein–Barr virus; ICC: intraclass correlation coefficient; LMICs: low- and middle-income countries; NPC: nasopharyngeal carcinoma; qPCR: quantitative polymerase chain reaction; ROC: receiver operating characteristic; RT: reverse transcription; VCA: viral capsid antigen

Conflict of interest: The authors declare no conflict of interest.

[†]Hospital Pulau Pinang: K.C. Pua (Project Leader), S. Subathra, N. Punithavati, B.S. Tan, Y.S. Ee, L.M. Ong, R.A. Hamid, M. Goh, J.C.T. Quah, J. Lim; Hospital Kuala Lumpur/Universiti Putra Malaysia: Y.Y. Yap, B.D. Dipak, R. Deepak, F.N. Lau, P.V. Kam, S. Shri Devi; Queen Elizabeth Hospital: C.A. Ong, C.L. Lum, Ahmad NA, Halimuddin S., M. Somasundran, A. Kam, M. Wodjin; Sarawak General Hospital/Universiti Malaysia Sarawak: S.K. Subramaniam, T.S. Tiong, T.Y. Tan, U.H. Sim, T.W. Tharumalingam, D. Norlida, M. Zulkarnaen, W.H. Lai; University of Malaya: G. Gopala Krishnan, C.C. Ng, A.Z. Bustam, S. Marniza, P. Shahfinaz, O. Hashim, S. Shamshinder, N. Prepageran, L.M. Looi, O. Rahmat, J. Amin, J. Maznan; Hospital Universiti Sains Malaysia: S. Hassan, B.Biswal; Cancer Research Initiatives Foundation: S.H. Teo, L. F. Yap; Institute for Medical Research: A.S.B. Khoo (Program Leader), A. Munirah, A. Subasri, L.P. Tan, W.R. Kim, X.J. Ng, V.M. Sivanesan, A.A. Anuar, F.I. Abdul Rahman, C.S.H. Ong, N.A. Adam, H. Siti Khodijah, M.D. Nor Soleha, S. Chew, G.W. Tan, N.M. Kumaran, M.S. Nurul Ashikin, M.S. Nursyazwani, B. Norhasimah, R. Sasela Devi, S. Shri Devi, C.Y. Koh.

Grant sponsor: Ministry of Health Malaysia; **Grant numbers:** NMRR-11-597-9667, NMRR-12-1183-14034, NMRR-16-1439-30762

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1002/ijc.32656

History: Received 8 Mar 2019; Accepted 15 Aug 2019; Online 8 Aug 2019

Correspondence to: Tan Lu Ping, Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Ministry of Health Malaysia, Jalan Pahang, 50588 Kuala Lumpur, Malaysia, Tel.: +603-2616-2727, Fax: +603-2616-2536, E-mail: luping@imr.gov.my